The Problem of Aducanumab for the Treatment of Alzheimer Disease

被引：36
|
作者：
Alexander, G. Caleb [1 ,2 ]
Karlawish, Jason [3 ]
机构：
[1] Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA
[2] Johns Hopkins Sch Med, Baltimore, MD USA
[3] Univ Penn, Philadelphia, PA 19104 USA
来源：
ANNALS OF INTERNAL MEDICINE | 2021年 / 174卷 / 09期
关键词：
D O I：
10.7326/M21-2603
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1303 / +
页数：3
相关论文
共 50 条
  • [41] Is Aducanumab treatment developed to prevent progression of Alzheimer's disease cost-effective in Turkey?
    Vahit Yigit
    Selin Kalender
    Iskender Cetinturk
    Cost Effectiveness and Resource Allocation, 21
  • [42] Is Aducanumab treatment developed to prevent progression of Alzheimer's disease cost-effective in Turkey?
    Yigit, Vahit
    Kalender, Selin
    Cetinturk, Iskender
    COST EFFECTIVENESS AND RESOURCE ALLOCATION, 2023, 21 (01)
  • [43] Should Canadian patients look forward to aducanumab for Alzheimer disease?
    Watt, Jennifer A.
    Marple, Roger
    Hemmelgarn, Brenda
    Straus, Sharon E.
    CANADIAN MEDICAL ASSOCIATION JOURNAL, 2021, 193 (43) : E1680 - E1682
  • [44] Aducanumab for Alzheimer's disease: expediting approval and delaying science
    Salinas, Rodrigo A.
    BMJ EVIDENCE-BASED MEDICINE, 2021, 26 (05) : 214 - 215
  • [45] Addendum: The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease
    Jeff Sevigny
    Ping Chiao
    Thierry Bussière
    Paul H. Weinreb
    Leslie Williams
    Marcel Maier
    Robert Dunstan
    Stephen Salloway
    Tianle Chen
    Yan Ling
    John O’Gorman
    Fang Qian
    Mahin Arastu
    Mingwei Li
    Sowmya Chollate
    Melanie S. Brennan
    Omar Quintero-Monzon
    Robert H. Scannevin
    H. Moore Arnold
    Thomas Engber
    Kenneth Rhodes
    James Ferrero
    Yaming Hang
    Alvydas Mikulskis
    Jan Grimm
    Christoph Hock
    Roger M. Nitsch
    Alfred Sandrock
    Nature, 2017, 546 : 564 - 564
  • [46] Approval of Aducanumab for Alzheimer Disease-the FDA's Perspective
    Dunn, Billy
    Stein, Peter
    Cavazzoni, Patrizia
    JAMA INTERNAL MEDICINE, 2021, 181 (10) : 1276 - 1278
  • [47] Regulatory decisions diverge over aducanumab for Alzheimer's disease
    Lythgoe, Mark P.
    Jenei, Kristina
    Prasad, Vinay
    BMJ-BRITISH MEDICAL JOURNAL, 2022, 376
  • [48] What the Aducanumab Approval Reveals About Alzheimer Disease Research
    Manly, Jennifer J.
    Glymour, M. Maria
    JAMA NEUROLOGY, 2021, 78 (11) : 1305 - 1306
  • [49] Lessons Learned from Approval of Aducanumab for Alzheimer's Disease
    Heidebrink, Judith L.
    Paulson, Henry L.
    ANNUAL REVIEW OF MEDICINE, 2024, 75 : 99 - 111
  • [50] Aducanumab: a new phase in therapeutic development for Alzheimer's disease?
    Lalli, Giovanna
    Schott, Jonathan M.
    Hardy, John
    De Strooper, Bart
    EMBO MOLECULAR MEDICINE, 2021, 13 (08)
12345